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Twenty-five years ago, Claude Grondin, a pioneer in the
development of coronary artery bypass grafting (CABG),
wrote an editorial in this Journal entitled ‘‘Late Results of
Coronary Artery Grafting: Is There a Flag on the Field?’’1
In that editorial, Grondin noted that long-term patencies of
saphenous vein grafts were significantly reduced as a conse-
quence of recurrent atherosclerotic disease. This observation
heralded the emergence of alternative percutaneous methods
to treat ischemic heart disease. The cardiac surgeon is now
faced with an increasing number of patients with multivessel
disease in whom previous percutaneous coronary inter-
ventions (PCIs) with coronary stents have already been per-
formed before CABG. In this edition of the Journal, Tran
and coworkers2 now report that patients with diabetes melli-
tus who have undergone stenting before CABG face an
increased risk of operative death, increased perioperative
complications, and decreased long-term survival. Does
coronary stenting predispose toward adverse outcomes
when CABG is subsequently needed? Is there another flag
on the field?
Previous studies have shown the superiority of CABG
relative to PCI in patients with diabetes and multivessel dis-
ease.3 With the advent of the drug-eluting stent (DES), it has
been suggested that stents will supplant CABG and become
the primary method of revascularization for patients with
diabetes mellitus.4 The endovascular changes seen in diabe-
tes mellitus, however, increase stent stenosis by accelerating
neointimal hyperplasia.5 Placing a foreign body, such as
a stent, in a coronary artery initiates an inflammatory
response that activates platelets andmacrophages. This leads
to remodeling of the extracellular matrix and smooth muscle
migration, which ultimately result in luminal narrowing.6 Al-
thoughDES use has been shown to decrease vascular smooth
muscle proliferation and reduce restenosis, the rate of reste-
nosis in patients with diabetes mellitus who receive DES
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without diabetes mellitus who receive this treatment.7,8 In
fact, the overall risk for stent thrombosis may be longer for
a DES than for a bare metal stent because of the slower rate
of re-endothelialization seen with the DES.9
In Tran and coworker’s series,2 patients with previous
PCI who underwent CABG had a significantly higher oper-
ative mortality (2.7% vs 1.0%), an increased risk of major
adverse cardiac events (MACEs), and a worse age-adjusted
survival at 2-year follow-up (93.4% vs 87.4%; P< .017).
There are, however, certain limitations inherent in the data-
base. The use of statin therapy in both groups was especially
low (<40%). The overall incidence of MACEs might have
been lowered had both groups received statins before
CABG. We also are not told whether the vessel that had
received a stent was bypassed and whether future ischemic
events could have been due to inadequate revascularization
of previously stented vessels. The incidences of type 1 dia-
betes in both groups are not documented, nor are the causes
of late deaths. Patients with diabetes mellitus, especially
those with type 1 disease, have higher incidences of cerebro-
vascular, renovascular, and peripheral vascular disease,
which could have accounted for the difference in long-
term survival. The type of stent used (DES vs bare metal
stent), the need for repeated revascularization, and the inci-
dence of vein graft stenosis are also not reported. The mecha-
nism for the decreased long-term survival in the CABG after
PCI group is thus unknown. Nevertheless, the data reported
by Tran and coworkers2 has been documented in other studies
involving patients undergoing CABG after previous PCIs.
Thielman and coworkers10 found that patients with diabetes
and multiple-vessel disease who underwent PCI before
CABG had higher risks of perioperative death and MACEs.
Gaudino and coworkers11 found that 5 years after CABG,
patients with a previous PCI had a lower saphenous vein graft
patency rate (45% vs 76.5%, P< .0001) and a higher inci-
dence of ischemia and recatheterization. Bonaros and co-
workers12 also noted that patients who had undergone
previous PCI before CABG had increased operative mortality
and MACE rate, required more blood products, had more
bleeding complications, and had a higher incidence of renal
failure requiring dialysis. In a multicenter analysis of 37,140
patients undergoing CABG, Massoudy and coworkers13
found that multiple previous PCIs significantly increased
hospital mortality and MACE rate.
What are the reasons for the increased morbidity and
mortality observed in patients who undergo CABG after
a previous PCI? Although the exact mechanisms arergery c August 2009
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with previous PCI require antiplatelet agents, which predis-
pose toward increased blood product use and blood loss.
Stents not only may result in local vascular inflammation
but may stimulate platelet and neutrophil adhesion along
the entire vessel, with resulting decreased graft patency. Be-
cause of the physical presence of the stent, bypass grafts may
need to be inserted more distally in vessels, which may com-
promise runoff and ultimately patency. Finally, as noted by
Tran and coworkers,2 patients undergoing CABG after PCI
represent a cohort with more advanced atherosclerotic dis-
ease, which is associated with reduced graft patency and re-
current ischemic events.
PCI with DESs is now being performed more often in
patients with diabetes and multivessel disease. If this trend
continues, perioperative and long-term results of CABG in
patients with previous PCI may not be as good as previously
reported. The long-term effects of DES use on vascular heal-
ing and remodeling remain unknown. It is, however, well
known that stents are prone to stenosis and thrombosis.
Will they also predispose toward less optimal outcomes after
CABG? Our medical colleagues should be alerted to the fact
that stenting for multiple-vessel disease may result in in-
creased morbidity and mortality after later CABG. I agree
that the Society of Thoracic Surgeons risk model should in-
clude all previous PCIs as a risk factor, and not just those per-
formed within 6 hours before surgery. Furthermore, our own
surgical colleaguesmaywish to curb their enthusiasm for hy-
brid CABG procedures that subject patients to multivessel
stenting so that they can perform a minimally invasive left
internal thoracic artery to left anterior descending coronary
artery anastomosis. It may come back to haunt them when
reoperative CABG is required. Twenty-five years after Gron-
din’s landmark editorial, we must now ask the question, doThe Journal of Thoracic andstents compromise the benefits of CABG surgery? Is there
now another flag on the field?
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